Erasca, Inc. (ERAS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Diego, CA, United States. The current CEO is Jonathan E. Lim.
ERAS has IPO date of 2021-07-16, 103 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $5.55B.
Erasca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapies for cancers driven by RAS/MAPK pathway alterations. The company's lead program, ERAS-007, is an oral ERK1/2 inhibitor in development for non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia, while ERAS-601, an oral SHP2 inhibitor, targets advanced and metastatic solid tumors. Erasca is also advancing ERAS-801, a CNS-penetrant EGFR inhibitor designed to treat recurrent glioblastoma multiforme. Founded in 2018 and headquartered in San Diego, California, the company aims to address significant unmet needs in oncology through precision-targeted drug development.
